Search

Your search keyword '"Clarissa Patrizi"' showing total 4 results
Start Over Author "Clarissa Patrizi" Publication Year Range Last 3 years
4 results on '"Clarissa Patrizi"'

1. Engineered Sleeping Beauty Transposon as Efficient System to Optimize Chimp Adenoviral Production

Author

Samantha Baldassarri, Daniela Benati, Federica D’Alessio, Clarissa Patrizi, Eleonora Cattin, Michela Gentile, Angelo Raggioli, and Alessandra Recchia

Subjects
Sleeping Beauty transposon, chimpanzee Adenovector production, precursor terminal protein, Biology (General), QH301-705.5, Chemistry, QD1-999
Abstract

Sleeping Beauty (SB) is the first DNA transposon employed for efficient transposition in vertebrate cells, opening new applications for genetic engineering and gene therapies. A transposon-based gene delivery system holds the favourable features of non-viral vectors and an attractive safety profile. Here, we employed SB to engineer HEK293 cells for optimizing the production of a chimpanzee Adenovector (chAd) belonging to the Human Mastadenovirus C species. To date, chAd vectors are employed in several clinical settings for infectious diseases, last but not least COVID-19. A robust, efficient and quick viral vector production could advance the clinical application of chAd vectors. To this aim, we firstly swapped the hAd5 E1 with chAd-C E1 gene by using the CRISPR/Cas9 system. We demonstrated that in the absence of human Ad5 E1, chimp Ad-C E1 gene did not support HEK293 survival. To improve chAd-C vector production, we engineered HEK293 cells to stably express the chAd-C precursor terminal protein (ch.pTP), which plays a crucial role in chimpanzee Adenoviral DNA replication. The results indicate that exogenous ch.pTP expression significantly ameliorate the packaging and amplification of recombinant chAd-C vectors thus, the engineered HEK293ch.pTP cells could represent a superior packaging cell line for the production of these vectors.

Published
2022
Full Text
View/download PDF

2. Supplementary Tables and Figure Legends from In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance through Inhibition of Caspase-3–Mediated Apoptosis

Author

Laura Gramantieri, Luigi Bolondi, Massimo Negrini, Matteo Ravaioli, Matteo Cescon, Catia Giovannini, Marzia Galassi, Maurizio Baldassarre, Elisa Callegari, Veronica Salvatore, Michele Baglioni, Marco Baron Toaldo, Giorgia Marisi, Andrea Casadei Gardini, Sara Marinelli, Tiziana La Bella, Clarissa Patrizi, Daniela Pollutri, and Francesca Fornari

Abstract

Supplementary Table S1. Characteristics of surgical HCC patients analysed in this study. Supplementary Table S2. Patients assessed for circulating miR-221. Supplementary Table S3. Primer sequences and PCR conditions for the cloning experiment. Supplementary Table S4. Primer sequences and PCR conditions. Supplementary Table S5. Antibodies used in Western blot analysis.

Published
2023

3. Supplementary Figure S2 from In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance through Inhibition of Caspase-3–Mediated Apoptosis

Author

Laura Gramantieri, Luigi Bolondi, Massimo Negrini, Matteo Ravaioli, Matteo Cescon, Catia Giovannini, Marzia Galassi, Maurizio Baldassarre, Elisa Callegari, Veronica Salvatore, Michele Baglioni, Marco Baron Toaldo, Giorgia Marisi, Andrea Casadei Gardini, Sara Marinelli, Tiziana La Bella, Clarissa Patrizi, Daniela Pollutri, and Francesca Fornari

Abstract

Figure S2. Histopathological images of HCC nodules arisen in DEN-treated rats following Sorafenib administration. Nodules that responded to Sorafenib displayed large necrotic areas.

Published
2023

4. Data from In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance through Inhibition of Caspase-3–Mediated Apoptosis

Author

Laura Gramantieri, Luigi Bolondi, Massimo Negrini, Matteo Ravaioli, Matteo Cescon, Catia Giovannini, Marzia Galassi, Maurizio Baldassarre, Elisa Callegari, Veronica Salvatore, Michele Baglioni, Marco Baron Toaldo, Giorgia Marisi, Andrea Casadei Gardini, Sara Marinelli, Tiziana La Bella, Clarissa Patrizi, Daniela Pollutri, and Francesca Fornari

Abstract

Purpose: The aberrant expression of miR-221 is a hallmark of human cancers, including hepatocellular carcinoma (HCC), and its involvement in drug resistance, together with a proved in vivo efficacy of anti-miR-221 molecules, strengthen its role as an attractive target candidate in the oncologic field. The discovery of biomarkers predicting the response to treatments represents a clinical challenge in the personalized treatment era. This study aimed to investigate the possible role of miR-221 as a circulating biomarker in HCC patients undergoing sorafenib treatment as well as to evaluate its contribution to sorafenib resistance in advanced HCC.Experimental Design: A chemically induced HCC rat model and a xenograft mouse model, together with HCC-derived cell lines were employed to analyze miR-221 modulation by Sorafenib treatment. Data from the functional analysis were validated in tissue samples from surgically resected HCCs. The variation of circulating miR-221 levels in relation to Sorafenib treatment were assayed in the animal models and in two independent cohorts of patients with advanced HCC.Results: MiR-221 over-expression was associated with Sorafenib resistance in two HCC animal models and caspase-3 was identified as its target gene, driving miR-221 anti-apoptotic activity following Sorafenib administration. Lower pre-treatment miR-221 serum levels were found in patients subsequently experiencing response to Sorafenib and an increase of circulating miR-221 at the two months assessment was observed in responder patients.Conclusions: MiR-221 might represent a candidate biomarker of likelihood of response to Sorafenib in HCC patients to be tested in future studies. Caspase-3 modulation by miR-221 participates to Sorafenib resistance. Clin Cancer Res; 23(14); 3953–65. ©2017 AACR.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results